Korro Bio Inc Sustainability Reports
Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company discovery-focused on developing a new class of genetic medicines based on editing RNA. Its proprietary platform leverages endogenous ADAR enzymes to make precise, single-base edits to treat rare and highly prevalent diseases.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00GFMTC47
2 reports from 2023 to 2024
Company Profile
Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company discovery-focused on developing a new class of genetic medicines based on editing RNA. Its proprietary platform leverages endogenous ADAR enzymes to make precise, single-base edits to treat rare and highly prevalent diseases.
Reports
2 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
